However, the data about whether polymorphisms in complement genes and other AMD risk factor genes can be used to predict the response to VEGFA‐targeted therapies are conflicting (Hagstrom et al., 2013, Smailhodzic et al., 2012). The gene discussed is VEGFA; the disease is age-related macular degeneration.